Evidence record · ER-IPAMORELIN-GH-007
Does ipamorelin trigger growth-hormone release?
Ipamorelin triggers short-term growth-hormone release in people
Ipamorelin can trigger an acute growth-hormone response in small human pharmacology studies. That supports only the short-term hormone-release claim under the tested conditions. It does not show improved recovery, muscle gain, fat loss, wellbeing or long-term safety, and it cannot verify the identity of an online vial.
Claim boundary
What this verdict covers
The supported outcome is an acute measured hormone response after a defined study product. The verdict does not extend to body composition, performance, recovery or anti-ageing claims.
- Compound
- Ipamorelin
- Population
- Adults in early human pharmacology studies
- Outcome
- Acute circulating growth hormone
- Record ID
- ER-IPAMORELIN-GH-007
Evidence synthesis
What the research can support
Early human studies examined ipamorelin as a selective growth-hormone secretagogue and measured hormone release. Later clinical development in other settings did not establish the broad consumer outcomes commonly attached to the peptide.
Why the confidence is moderate
Participant numbers and follow-up were limited, and hormone release is a surrogate endpoint. Product identity and differences in formulation remain outside the trials.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-IPAMORELIN-GH-007 addresses one bounded question: Does ipamorelin trigger growth-hormone release?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 4 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Limited human, the verdict is Supported and confidence is Moderate. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| Human ipamorelin pharmacology study | The study reported selective growth-hormone release after ipamorelin. | It did not test recovery or body composition. | 10 August 2026 |
| Clinical ipamorelin development study | The paper provides human clinical-development data in a defined setting. | It does not establish broad wellness or performance claims. | 10 August 2026 |
| FDA ipamorelin safety briefing | FDA reviewed the evidence and safety limitations for compounded ipamorelin. | It does not verify a consumer vial. | 10 August 2026 |
| WADA 2026 Prohibited List | Growth hormone secretagogues are prohibited at all times. | Sport rules do not establish medical benefit. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Ipamorelin for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
Early human studies examined ipamorelin as a selective growth-hormone secretagogue and measured hormone release. Later clinical development in other settings did not establish the broad consumer outcomes commonly attached to the peptide. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Ipamorelin authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Growth hormone secretagogues, including ipamorelin, are prohibited at all times under the WADA S2 category. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion. Read the cited source and stated scope together before relying on it.
What could change this verdict?
Independent controlled studies measuring clinical or functional outcomes, with adequate duration, product characterisation and systematic safety monitoring. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation